Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 84,738 shares at $41.72 ($3.5M) on 2021-07-02, disclosed to the SEC on 2021-07-06.
Open-market sale of $3.5M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.22 | 13,268 | $547K | 15.6% |
| 2 | $41.22 | 8,650 | $357K | 10.2% |
| 3 | $41.22 | 13,268 | $547K | 15.6% |
| 4 | $41.89 | 1,112 | $47K | 1.3% |
| 5 | $41.89 | 728 | $30K | 0.9% |
| 6 | $42.75 | 30 |
| $1K |
| 0.0% |
| 7 | $42.75 | 46 | $2K | 0.1% |
| 8 | $41.08 | 8,627 | $354K | 10.1% |
| 9 | $41.08 | 5,626 | $231K | 6.6% |
| 10 | $41.08 | 5,626 | $231K | 6.6% |
| 11 | $41.08 | 8,627 | $354K | 10.1% |
| 12 | $41.72 | 5,789 | $242K | 6.9% |
| 13 | $41.72 | 3,776 | $158K | 4.5% |
| 14 | $41.72 | 5,789 | $242K | 6.9% |
| 15 | $41.72 | 3,776 | $158K | 4.5% |
| Total | $41.30 avg | 84,738 | $3.5M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |